Should Pharma Be Concerned About Cooling China-Korea Ties?
Executive Summary
Despite regional defense policy concerns that have prompted broad moves to limit economic exchanges between China and South Korea, which could also potentially affect ever expanding healthcare collaborations between the two countries, the pharma sector impact so far appears to be limited.
You may also be interested in...
Yuhan, Luoxin Deal Underscores Asian NSCLC Therapy Needs
Yuhan and Luoxin's licensing agreement for a third generation EGFR inhibitor, the second such deal between South Korea and China, suggests robust demand for novel drugs for non-small cell lung cancer in Asia.
China Biobetter EPO Deal Seen Boosting Genexine’s Prospects
Following deals last year in China and ASEAN, Genexine has now inked a $44.5m agreement with a subsidiary of Shanghai Fosun Pharmaceutical to license out a novel long-acting EPO for anemia. The deal is set to further buoy the South Korean bioventure’s global presence and beef up the Chinese firm’s pipeline.
Hanmi’s Roll Continues With ZAI China Cancer Deal
Hanmi is continuing to reap big dividends this year from its original R&D efforts. Following a major licensing out deal with Boehringer Ingelheim for a novel lung cancer therapy in July, the South Korean firm has now reached an additional licensing agreement for the therapy with ZAI Lab for China, Hong Kong and Macau, in a deal that will bolster the Chinese biopharma's growing oncology portfolio.